Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel

Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca

Entheon Biomedical Announces EEG Patent Application & Provides Research Update

Entheon to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Entheon ID(TM) Clinical Study to Assess the Effect of Ketamine on Neurological Activity as Measured by EEG